Vitiligo as an inflammatory skin disorder: A therapeutic perspective

Pigment Cell and Melanoma Research

Volumn 25, Issue 1, 2012, Pages 9-13

  Taïeb, Alain ^a  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

Melanocytes; Vitiligo; White macules

Indexed keywords

ATOPIC DERMATITIS; HUMAN; IMMUNE RESPONSE; MELANOCYTE; NONHUMAN; NOTE; PSORIASIS; SKIN DISEASE; SKIN INFLAMMATION; VITILIGO;

ADAPTIVE IMMUNITY; ANIMALS; DISEASE MODELS, ANIMAL; HAIR FOLLICLE; HUMANS; IMMUNITY, INNATE; INFLAMMATION; MELANOCYTES; MODELS, BIOLOGICAL; REGENERATIVE MEDICINE; SKIN; SKIN PIGMENTATION; T-LYMPHOCYTES, REGULATORY; TRANSLATIONAL MEDICAL RESEARCH; VITILIGO;

EID: 83955165240     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2011.00939.x     Document Type: Note

References (40)

1. Bassiouny, D.A., and Shaker, O. (2011). Role of interleukin-17 in the pathogenesis of vitiligo. Clin. Exp. Dermatol. 36, 292-297.
2. Ben Ahmed, M., Zara, I., Reki, R., Elbeldi-Ferchio, A., Kourda, N., Belhadj Hmida, N., Abdeladhim, M., Karoui, O., Ben Osman, A., Mokni, M., and Louzir, H. (2011). Functional defects of peripheral regulatory T lymphocytes in patients with progressive vitiligo. Pigment Cell Melanoma Res. doi: 10.1111/j.1755-148X.2011.00920.x.
3. Birle, S.A., Ji, Y., Bennett, D.C., Herbstman, D.M., Wallace, M.R., McCormack, W.T., Kemp, E.H. et al. (2011). Comprehensive association analysis of candidate genes for generalized vitiligo supports XBP1, FOXP3, and TSLP. J. Invest. Dermatol. 131, 371-381.
4. Böhm, M (2010). Other immunosuppressive regimen. In Vitiligo, M. Picardo, and A. Taieb, eds. (Heidelberg: Springer), pp. 381-385.
5. van den Boorn, J.G., Picavet, D.I., van Swieten, P.F., van Veen, H.A., Konijnenberg, D., vanVeelen, P.A., van Capel, T. et al. (2011). Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy. J. Invest. Dermatol. 131, 1240-1251.
6. Boralevi, F., Hubiche, T., Léauté-Labrèze, C., Saubusse, E., Fayon, M., Roul, S., Maurice-Tison, S., and Taïeb, A. (2008). Epicutaneous aeroallergen sensitization in atopic dermatitis infants - determining the role of epidermal barrier impairment. Allergy 63, 205-210.
7. Denman, C.J., McCracken, J., Hariharan, V., Klarquist, J., Oyarbide-Valencia, K., Guevara-Patiño, J.A., and Le Poole, I.C. (2008). HSP70i accelerates depigmentation in a mouse model of autoimmune vitiligo. J. Invest. Dermatol. 128, 2041-2048.
8. Di Cesare, A., Di Meglio, P., and Nestle, F.O. (2009). The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J. Invest. Dermatol. 129, 1339-1350.
9. Eleftheriadou, V., Whitto, M.E., Gawkrodger, D.J., Batchelor, J., Corne, J., Lamb, B. et al. (2011). Vitiligo priority setting partnership. Future research into the treatment of vitiligo: where should our priorities lie? Results of the vitiligo priority setting partnership. Br. J. Dermatol. 164, 530-536.
10. Ezzedine, K., Gauthier, Y., Léauté-Labrèze, C., Marquez, S., Bouchtnei, S., Jouary, T., and Taieb, A. (2011a). Segmental vitiligo associated with generalized vitiligo (mixed vitiligo): a retrospective case series of 19 patients. J. Am. Acad. Dermatol. 65, 965-971.
11. Ezzedine, K., Diallo, A., Léauté-Labrèze, C., Mossalayi, D., Gauthier, Y., Bouchtnei, S., Cario-André, M. et al. (2011b). Multivariate analysis of factors associated with early-onset segmental and nonsegmental vitiligo: a prospective observational study of 213 patients. Br. J. Dermatol. 165, 44-49.
12. Ezzedine, K., Diallo, A., Léauté-Labrèze, C., Séneschal, J., Prey, S., Ballanger, F., Alghamdi, K., Cario-André, M., Jouary, T., Gauthier, Y., and Taieb, A. (2011c). Halo nevi and leukotrichia are strong predictors of the passage to mixed vitiligo in a subgroup of segmental vitiligo. Br. J. Dermatol. doi: 10.1111/j.1365-2133.2011.10709.x.
13. Ezzedine, K., Diallo, A., Léauté-Labrèze, C., Séneschal, J., Mossalayi, D., AlGhamdi, K., Prey, S. et al. (in press). Halo nevi association in nonsegmental vitiligo influences age of onset and depigmentation pattern. Arch. Dermatol. doi: 10.1111/j.1755-148X.2011.00916.x.
14. van Geel, N.A., Mollet, I.G., De Schepper, S., Tjin, E.P., Vermaelen, K., Clark, R.A., Kupper, T.S. et al. (2010). First histopathological and immunophenotypic analysis of early dynamic events in a patient with segmental vitiligo associated with halo nevi. Pigment Cell Melanoma Res. 23, 375-384.
15. van Geel, N., Speeckaert, R., Taieb, A., Picardo, M., Böhm, M., Gawkrodger, D.J., Schallreuter, K. et al. (2011a). Koebner's phenomenon in vitiligo: European position paper. Pigment Cell Melanoma Res. 24, 564-573.
16. van Geel, N., Speeckaert, R., Mollet, I., De Schepper, S., De Wolf, J., Tjin, E.P., Luiten, R.M., Lambert, J., and Brochez, L. (2011b). In vivo vitiligo induction and therapy model: double-blind, randomized clinical trial. Pigment Cell Melanoma Res. doi: 10.1111/j.1755-148X.2011.00922.x.
17. Goudie, R.B., Soukop, M., Dagg, J.H., and Lee, F.D. (1990). Hypothesis: symmetrical cutaneous lymphoma. Lancet 335, 316-318.
18. Gregg, R.K., Nichols, L., Chen, Y., Lu, B., and Engelhard, V.H. (2010). Mechanisms of spatial and temporal development of autoimmune vitiligo in tyrosinase-specific TCR transgenic mice. J. Immunol. 2010, 184.
19. Hollox, E.J., Huffmeier, U., Zeeuwen, P.L., Palla, R., Lascorz, J., Rodijk-Olthuis, D., van de Kerkhof, P.C. et al. (2008). Psoriasis is associated with increased beta-defensin genomic copy number. Nat. Genet. 40, 23-25.
20. Jin, Y., Mailloux, C.M., Gowan, K., Riccardi, S.L., LaBerge, G., Bennett, D.C., Fain, P.R., and Spritz, R.A. (2007). NALP1 in vitiligo-associated multiple autoimmune disease. N. Engl. J. Med. 356, 1216-1225.
21. Jin, Y., Birlea, S.A., Fain, P.R., Mailloux, C.M., Riccardi, S.L., Gowan, K., Holland, P.J. et al. (2010a). Common variants in FOXP1 are associated with generalized vitiligo. Nat. Genet. 42, 576-578.
22. Jin, Y., Birlea, S.A., Fain, P.R., Gowan, K., Riccardi, S.L., Holland, P.J., Mailloux, C.M. et al. (2010b). Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. N. Engl. J. Med. 362, 1686-1697.
23. Jin, Y., Birlea, S.A., Fain, P.R., Gowan, K., Riccardi, S.L., Holland, P.J., Bennett, D.C. et al. (2011). Genome-wide analysis identifies a quantitative trait locus in the MHC class II region associated with generalized vitiligo age of onset. J. Invest. Dermatol. 131, 1308-1312.
24. Joly, P. (2006). The use of methotrexate alone or in combination with low doses of oral corticosteroids in the treatment of alopecia totalis or universalis. J. Am. Acad. Dermatol. 55, 632-636.
25. Klarquist, J., Denman, C.J., Hernandez, C., Wainwright, D.A., Strickland, F.M., Overbeck, A., Mehrotra, S. et al. (2010). Reduced skin homing by functional Treg in vitiligo. Pigment Cell Melanoma Res. 23, 276-286.
26. Kroll, T.M., Bommiasamy, H., Boissy, R.E., Hernandez, C., Nickoloff, B.J., Mestril, R., and Le Poole, I.C. (2005). 4-Tertiary butyl phenol exposure sensitizes human melanocytes to dendritic cell-mediated killing: relevance to vitiligo. J. Invest. Dermatol. 124, 798-806.
27. Mosenson, J.A., Zloza, A., Klarquist, J., Barfuss, A.J., Guevara-Patino, J.A., and Le Poole, I.C. (2011). HSP70i is a critical component of the immune response leading to vitiligo. Pigment Cell Melanoma Res. doi: 10.1111/j.1755-148X.2011.00916.x.
28. Muranski, P., Boni, A., Antony, P.A., Cassard, L., Irvine, K.R., Kaiser, A., and Paulos, C.M. (2008). Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112, 362-373.
29. Nicolaidou, E., Antoniou, C., Miniati, A., Lagogianni, E., Matekovits, A., Stratigos, A., and Katsambas, A. (2011). Childhood- and later-onset vitiligo have diverse epidemiologic and clinical characteristics. J. Am. Acad. Dermatol. doi: 10.1016/j.jaad.2011.07.010.
30. + T cells. J. Exp. Med. 198, 569-580.
31. Palmer, C.N., Irvine, A.D., Terron-Kwiatkowski, A., Zhao, Y., Liao, H., Lee, S.P., Goudie, D.R. et al. (2006). Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat. Genet. 38, 441-446.
32. Picardo, M., and Taieb, A. (2010). Vitiligo. (Heidelberg: Springer).
33. Quan, C., Ren, Y.Q., Xiang, L.H., Sun, L.D., Xu, A.E., Gao, X.H., Chen, H.D. et al. (2010). Genome-wide association study for vitiligo identifies susceptibility loci at 6q27 and the MHC. Nat. Genet. 42, 614-618.
34. Silva de Castro, C.C., do Nascimento, L.M., Olandoski, M., and Mira, M.T. (2011). A pattern of association between clinical form of vitiligo and disease-related variables in a Brazilian population. J. Dermatol. Sci. doi: 10.1016/j.jdermsci.2011.09.011.
35. Taïeb, A., and Picardo, M. (2009). Clinical practice. Vitiligo. N. Engl. J. Med. 360, 160-169.
36. Taïeb, A., Morice-Picard, F., Jouary, T., Ezzedine, K., Cario-André, M., and Gauthier, Y. (2008). Segmental vitiligo as the possible expression of cutaneous somatic mosaicism: implications for common non-segmental vitiligo. Pigment Cell Melanoma Res. 21, 646-652.
37. Taïeb, A., Seneschal, J., and Mossalayi, M.D. (2011). Biologics in atopic dermatitis. J. Dtsch Dermatol. Ges. doi: 10.1111/j.1610-0387.2011.07760.x.
38. Wang, X., and Erf, G.F. (2003). Melanocyte-specific cell mediated immune response in vitiliginous Smyth line chickens. J. Autoimmun., 21, 149-160.
39. Wang, C.Q., Cruz-Inigo, A.E., Fuentes-Duculan, J., Moussai, D., Gulati, N., Sullivan-Whalen, M., Gilleaudeau, P. et al. (2011). Th17 cells and activated dendritic cells are increased in vitiligo lesions. PLoS One 6, e18907.
40. + T cells at the perilesional site. Lab. Invest. 80, 1299-1309.